Brain 11β-Hydroxysteroid Dehydrogenase Type 1 Occupancy by Xanamem™ Assessed by PET in Alzheimer’s Disease and Cognitively Normal Individuals

Author:

Villemagne Victor L.12,Doré Vincent13,Chong Lee1,Kassiou Michael4,Mulligan Rachel15,Feizpour Azadeh15,Taylor Jack6,Roesner Miriam6,Miller Tamara6,Rowe Christopher C.15

Affiliation:

1. Department of Molecular Imaging and Therapy, Austin Health, Melbourne, VA, Australia

2. Department of Psychiatry, The University of Pittsburgh, Pittsburgh, PA, USA

3. CSIRO e-Health Research Centre, Brisbane, QLD, Australia

4. The University of Sydney, School of Chemistry, Sydney, Australia

5. Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Melbourne, VA, Australia

6. Actinogen Medical, Sydney, NSW, Australia

Abstract

Background: 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) regulates intracellular cortisol and its inhibition by the small molecule inhibitor, Xanamem™, may provide a disease-modifying strategy for Alzheimer’s disease (AD). Animal models suggest a range of 30–60% enzyme inhibition may suffice to provide neuroprotection. Objective: To determine the regional brain occupancy of 11β-HSD1 by Xanamem™ in cognitively normal participants (CN) and mild cognitive impairment (MCI)/mild AD patients to investigate potential dosing ranges for future efficacy studies. Methods: Seventeen MCI/AD and 23 CN were included. Regional brain time-activity curves (TAC), standardized uptake values (SUV40–60) and volume of distribution (VT) from Logan plot with image derived input function from 11C-TARACT positron emission tomography (PET) were used to assess the degree of 11β-HSD1 occupancy by increasing doses of Xanamem™ (5 mg, 10 mg, 20 mg or 30 mg daily for 7 days). Results: All measures showed high 11β-HSD1 occupancy with Xanamem to similar degree in CN and MCI/AD. The dose-response relationship was relatively flat above 5 mg. Respective median (interquartile range [Q1-Q3]) 11β-HSD1 occupancy in the MCI/AD and CN groups after treatment with 10 mg Xanamem were 80% [79–81%] and 75% [71–76%] in the neocortex, 69% [64–70%] and 61% [52–63%] in the medial temporal lobe, 80% [79–80%] and 73% [68–73%] in the basal ganglia, and 71% [67–75%] and 66% [62–68%] in the cerebellum. Conclusions: TAC, SUV40–60, and VT measures indicate Xanamem achieves high target occupancy levels with near saturation at 10 mg daily. These data support exploration of doses of≤10 mg daily in future clinical studies.

Publisher

IOS Press

Subject

Psychiatry and Mental health,Geriatrics and Gerontology,Clinical Psychology,General Medicine,General Neuroscience

Reference39 articles.

1. Eisai, Inc. (2012) ARICEPT® (donepezil hydrochloride) prescribing information. https://www.accessdata.fda.gov/drugsatfda docs/label/2012/020690s035,021720s008,022568s005lbl.pdf, Last updated February 2012, Accessed on March 3, 2022.

2. Abbvie (2020) NAMENDA® (memantine hydrochloride) prescribing information. https://media.allergan.com/actavis/actavis/media/allergan-pdf-documents/productprescribing/Final-Clean-Namenda-USPI.pdf, last updated November 2018, Accessed on March 3, 2022.

3. Two randomized phase 3 studies of aducanumab in early Alzheimer’s disease;Budd Haeberlein;J Prev Alzheimers Dis,2022

4. Lecanemab in early Alzheimer’s disease;van Dyck;N Engl J Med,2023

5. Glucocorticoids increase amyloid-β and tau pathology in a mouse model of Alzheimer’s disease;Green;J Neurosci,2006

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3